Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.56 |
| ▸ | CMA1 | P23946 | 10/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17081787 | 1.00 | ACE (0.56) | ACECMA1KLK5F2PRSS1 | |
| SCHEMBL10053455 | 1.00 | ACE (0.56) | ACECMA1KLK5F2PRSS1 | |
| SCHEMBL5971091 | 0.90 | ACE (0.59) | ACECMA1KLK5F2PRSS1 | |
| SCHEMBL7321218 | 0.86 | ACE (0.60) | ACECMA1KLK5F2PRSS1 | |
| SCHEMBL8365663 | 0.84 | ACE (0.56) | ACECMA1KLK5F2PRSS1 | |
| SCHEMBL28002546 | 0.84 | KLK5 (0.69) | ACECMA1KLK5F2PRSS1 | |
| SCHEMBL7268512 | 0.84 | KLK5 (0.69) | ACECMA1KLK5F2PRSS1 | |
| SCHEMBL28002552 | 0.84 | KLK5 (0.69) | ACECMA1KLK5F2PRSS1 | |
| SCHEMBL12658455 | 0.84 | KLK5 (0.69) | ACECMA1KLK5F2PRSS1 | |
| SCHEMBL8366819 | 0.83 | DPP4 (0.58) | ACEKLK5F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133237-B2 | Cyclic peptides with an anti-parasitic activity | UNIVERSITE JOSEPH FOURIER (GRENOBLE 1) (FR) | 2015-09-15 | — | — | US | disclosed |
| US-20120034593-A1 | CYCLIC PEPTIDES WITH AN ANTI-PARASITIC ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034593-A1 | CYCLIC PEPTIDES WITH AN ANTI-PARASITIC ACTIVITY | VIP, NGLY1, QPCT | ACE 2104/4885CMA1 803/4885KLK5 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.